4th Quarter - Report

CSL BEHRING LLC for CSL BEHRING LLC

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Government Issues GOV

Multiple proposals to strengthen Foreign Agents Registration Act, including S. 2039/HR 4170, Disclosing Foreign Influence Act--US Lobbying registration requirements for international companies

Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.

LobbyistCovered position, as disclosed
JULIA GRANT —

Contacted: Food & Drug Administration (FDA); Treasury, Dept of; HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2039 (115th), H.R. 4170 (115th)

Taxation/Internal Revenue Code TAX

H.R. 7324--Preserving Access to Orphan Drugs Act--Orphan Drugs Exclusion from the Branded Annual Pharmaceutical Fee

Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.

LobbyistCovered position, as disclosed
PATRICK COLLINS —
JULIA GRANT —
DENNIS JACKMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Treasury, Dept of; Food & Drug Administration (FDA)

Bills named: H.R. 7324 (115th)

Health Issues HCR

H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act

Foreign entity interest: CSL Limited, identified on form LD-1, has an interest in the activities of its U.S. subsidiary CSL Behring on all issues.

LobbyistCovered position, as disclosed
PATRICK COLLINS —
JULIA GRANT —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Treasury, Dept of

Bills named: H.R. 4724 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.